MULTIDRUG RESISTANT ACINETOBACTER SPECIES: A RISING CONCERN: RESTORATION OF OLD ANTIBIOTICS.

Main Article Content

Sangeeta Panigrahy
Sravanthi Mude
Aruna Rani Behera
Dr. P. Samatha
Ch. Suryamani
Bala Chandrasekhar. P

Keywords

Minocycline, Multi-Drug Resistant Acinetobacter

Abstract

Background


Acinetobacter species, resilient in the face of multiple drugs, have become a prevalent presence in hospital settings and among patients. The formidable array of resistance mechanisms they accumulate not only restricts treatment options but also amplifies the challenge of combating infections, significantly elevating the risk of mortality.


Materials and Methods


This prospective study took place in the Department of Microbiology at GEMS and Hospital from November 2022 to June 2023,


Results: 150 multidrug-resistant Acinetobacter isolates were collected from the ICU and various Wards. Maximum MDR isolates were found in the ICU. Pus samples showed the highest multidrug-resistant followed by ET aspirate and Blood. Among 150 MDR isolates, our isolates showed high resistance to ceftriaxone85 (100%), cefoperazone sulbactam 85(100%), amikacin 85(100%), gentamicin 83 (97.6%), cotrimoxazole 75 (88.2%) and ciprofloxacin78 (91.7%) followed by imipenem 78 (91.7%), Piperacillin – tazobactam 81 (95.2%), tigecycline 68 (80%), colistin 61 (71.7%). Susceptibility rates of MDR Acinetobacter strains to minocycline showed better susceptibility by E-test method 78 (91.7%) compared to disk diffusion method 71 (83.5%) and highest susceptibility of minocycline in pus samples followed by ET aspiration and blood and least susceptibility in urinary tract infection where minocycline does not respond well.


 Conclusion: This research underscores the enduring effectiveness of minocycline as a therapeutic choice against MDR-AB. Notably, the E-test demonstrates superior sensitivity when contrasted with the disk diffusion test, adding a layer of precision to our understanding of treatment dynamics

Abstract 95 | pdf Downloads 83

References

1. Taneja N, Singh G, Singh M, Sharma M. 2011. The emergence of tigecycline & colistin-resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res 133:681–684.
2. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity was tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in the US and European medical centers (2012). Int J Antimicrob Agents 2014;43:533-9.
3. Bishburg E, Bishburg K. Minocycline—an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents 2009;34:395–401.
4. Castanheira M, Mendes RE, Jones RN. 2014. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis 59(Suppl 6):S367–S373. http://dx.doi.org/10.1093/cid/ciu706.
5. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58:256–65. 16.
6. Welling PG, Shaw WR, Uman SJ, Tse FLS, Craig WA. Pharmacokinetics of minocycline in renal failure. Antimicrob Agents Chemother 1975; 8:532–Minocin [package insert]. San Diego, CA: Rempex Pharmaceuticals, 2013.
7. Jingyi Shi, et al, Multidrug-resistant and extensively drug-resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit, BMC Infectious Diseases volume 20, Article number: 597 (2020)
8. S. Jayashree1, K.G. Rajeshwari2 and Mita D. Wadekar1 Drug Resistance Mechanism among Acinetobacter Species J Pure Appl Microbiol. 2021
9. Zeina A. Kanafani et al, multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon Antimicrobial Resistance & Infection Control volume 7, Article number: 9 (2018)
10. Taghreed A. Hafiz et al, A two-year retrospective study of multidrug-resistant Acinetobacter baumannii respiratory infections in critically Ill patients: Clinical and microbiological findings Journal of Infection and Public Health Volume 16, Issue 3, March 2023.
11. Zeleke Ayenew et al, Multidrug resistance pattern of Acinetobacter species isolated from clinical specimens referred to the Ethiopian PublicHealth Institute: 2021 Apr 29.
12. Most of S, Mirnejad R, Faramaz M. Multi-drug resistance in Acinetobacter baumannii strains isolated from clinical specimens from three hospitals in Tehran-Iran. African J Microbiol Res. 2011; 5:3579–82.
13. Vijayan Sivaranjani et al, multi-drug resistant Acinetobacter species from various clinical samples in a tertiary care hospital from South India, Australas Med J. 2013; 6(12): 697–700.
14. Shakibaie MR, Adeli S, Salehi MH. Antibiotic resistance patterns and extended-spectrum beta-lactamase production among Acinetobacter spp. isolated from an intensive care Unit of a hospital in Kerman, Iran. Antimicrob Resist Infect Control. 2012; 1:1.
15. Peng Wang et al, Comparison of Minocycline Susceptibility Testing Methods for Carbapenem Resistant Acinetobacter baumannii , J Clin Microbiol. 2016 Dec; 54(12): 2937–2941. 2016 Nov 23.
16. H. Adibhesami et al, Minocycline activity against clinical isolates of multidrug-resistant Acinetobacter baumannii. Clin Microbiol Infect 2015

Most read articles by the same author(s)